Neuropathy & Nerve Health — Peptide Research Overview
Peripheral neuropathy and central nervous system injuries represent some of the most difficult conditions to treat in medicine, as the nervous system has limited regenerative capacity. Several peptide compounds have demonstrated neuroprotective and neuroregenerative properties that may help restore nerve function, reduce pain, and support recovery from neurological injury.
Relevant Compounds
- Cerebrolysin — Porcine brain-derived peptide mixture with BDNF-like, CNTF-like, and IGF-like activity. Used clinically for stroke, traumatic brain injury, and Alzheimer's disease in Europe and Asia.
- BPC-157 — Shown to promote peripheral nerve regeneration and protect against neurotoxin-induced damage in animal models.
What the Research Shows
Cerebrolysin
[Human Trial] Cerebrolysin is registered as a drug in over 50 countries and has been evaluated in multiple RCTs for stroke recovery, Alzheimer's disease, and traumatic brain injury. The CASTA trial (ischemic stroke) showed improved neurological outcomes at day 90 in patients receiving Cerebrolysin vs. placebo, particularly in those with severe strokes. A Cochrane review acknowledges the positive trial data while noting methodological heterogeneity. The proposed mechanism involves a mixture of low-molecular-weight neuropeptides (BDNF, CNTF, GDNF mimetics) that promote neuronal survival, axonal sprouting, and synaptic plasticity. Peripheral neuropathy applications are less studied but biologically plausible given the neurotrophic mechanism.
BPC-157
[Animal Study] BPC-157 has demonstrated nerve repair activity in rodent models of sciatic nerve crush injury — one of the standard models for peripheral neuropathy research. Treated animals show faster recovery of paw withdrawal reflexes, improved nerve conduction velocities, and histological evidence of remyelination. BPC-157 also protects against neurotoxin-induced dopaminergic neuron damage, suggesting broader neuroprotective activity beyond peripheral nerve repair.
Evidence Summary
| Compound | Evidence Level | Primary Application |
|---|---|---|
| Cerebrolysin | Human Trial | Stroke recovery, TBI, Alzheimer's; CNS neuroprotection |
| BPC-157 | Animal Study | Peripheral nerve regeneration, remyelination, neurotoxin protection |
Research Disclaimer
No compound listed on this page is FDA-approved for neuropathy or nerve health in the United States. Cerebrolysin is approved in other countries. BPC-157 has no human trial data for neuropathy. This page is an educational summary of existing research. Consult your neurologist or healthcare provider before using any compound.
Track your compounds with Dosi
Log doses, monitor symptoms, and build a personal health timeline. Free to start.
Start Tracking Free →Educational use only. This content is for informational purposes only and does not constitute medical advice. Individual results vary. Always consult a licensed healthcare provider before starting any compound.